期刊文献+

虚拟化合物的可专利性研究

Research on Patentability of the Virtual Compound
下载PDF
导出
摘要 先导化合物是现代新药研发的出发点,发现和寻找先导化合物有多种多样的途径和方法。虚拟化合物是一种基于受体结构的三维信息,采用计算机辅助药物设计技术设计出的能与受体特异性结合的先导化合物。是否保护专利化合物的虚拟形式使用和由此产生的虚拟化合物是决定这一全新药物设计方法广泛普及和向前发展的关键所在。 The lead compound is the starting point of the development of modern medicine.There are a lot of methods in discovering and distinguishing the lead compounds.Virtual compound,based on three -dimensional receptor structural in-formation and employs computer aided drug design methods,generates and optimizes the lead compound.Whether or not to protect of the virtual form use of a chemical compound and virtual compound is the key factor to popularize and develop the De Novo design.
作者 胡允银
机构地区 台州学院
出处 《科技管理研究》 CSSCI 北大核心 2014年第20期172-174,共3页 Science and Technology Management Research
基金 国家社科基金项目"‘战略-形象’协同视角下国家知识产权形象建设研究"(13BGL003)
关键词 全新药物设计 虚拟化合物 可专利性 De Novo drug design virtual compound patentability
  • 相关文献

参考文献10

  • 1JOSEPH A DIMASI, RONALD W HANSEN, HENRY G GRABOWS- KI. The price of innovation : New estimates of drug development costs [J]. Journal of Health Economics, 2003 (22) : 151 -185.
  • 2MATTHEW I-IERPER. The truly staggering cost of inventing new drugs [DB/OL]. (2012-03-23) [2014-03-01]. http: // forbesindia, corn/article/ideas - opinlons/the - truly - staggering - cost - of - inventing - new - drugs325801 ? utm slidebox.
  • 3BRUCE R GELIN. Current approaches in computer - aided molecular design [ M]. Cambridge: Cambridge university press, 1995.
  • 4张珉,张万年,宋云龙,盛春泉.全新药物设计方法的新进展[J].药学进展,2003,27(6):327-332. 被引量:2
  • 5ROGER BARRETT. Discretionary use of the doctrine of equivalents in patent law : Going beyond the triple identity test of graver tank [ J ]. University of Hawaii Law Review, 1995 (17) : 513 -533.
  • 6TED L FIELD. Comment, computer - aided drug design using paten- ted compounds: Infringement in cyberspace? [ J]. University of Mar- shall Law Review, 2001 (34) : 1001 - 1018.
  • 7TREVOR J SMEDLEY, ROSS A DANNENBERG. Enforceability of machine patents in virtual worlds [J] Internet Journal of Law, Healthcare and Ethics, 2010 (13) : 16 -17.
  • 8LEXIS NEXIS PATENT COMMUNITY. Fort Props. , Inc. v. Am. Master Lease LLC [ EB/OL]. (2012 - 03 - 01 ) [ 2014 - 03 - 01]. http: //www. lexisnexis, com/|egalnewsroom/intellectual- property/b/patent - law - blog/archive/2012/03/01/top - 10 - pa- tent - cases - for - the - month - of- february - 2012. aspx.
  • 9BECK, TYSVER. Gottschalk v. Benson [DB/OL] . [2014-03- 01]. http: //www. bitlaw, corn/source/mpep/2106, html.
  • 10ALEX NIE. Research Corp. Techs., Inc. v. Microsoft Corp. [ DB/ OL]. (2010-12-08) [2014-03-01]. http: //www. foley. corn/files/Article. 3 patentEligibilitychinaNewsletterSping2011 pdf.

二级参考文献30

  • 1[1]Kellogg G E, Semus S F, Abraham D J. HINT: a new method of empirical hydrophobic field calculation for CoMFA [ J ]. J Comput Aided Mol Des, 1991,5:545-552.
  • 2[2]Laskowski R A, Thornton J M, Humblet C, et al. X-SITE:use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins[J]. J Mol Biol, 1996,259:175-201.
  • 3[3]Verdonk M L, Cole J C, Taylor R. SuperStar: a knowledgebased approach for identifying interaction sites in proteins[J].J Mol Biol, 1999,289:1093-1108.
  • 4[4]Rotstein S H, Murcko M A. GroupBuild: a fragment-based method for de novo drug design[J]. J Med Chem, 1993,36:1700-1710.
  • 5[5]Bohacek R S, McMartin C. Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth[J]. JAm Chem Soc, 1994,116:5560-5571.
  • 6[6]Gehlhaar D K, Moerder K E, Zichi D, et al. De novo design of enzyme inhibitors by Monte Carlo ligand generation[J]. J Med Chem , 1995,38:466-472.
  • 7[7]Eisen M B, Wiley D C, Karplus M, et al. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site[J]. Proteins, 1994,19:199-221.
  • 8[8]Budin N, Majeux N, Souaille C T, et al. Strucuture-based ligand design by a build-up approach and generic algorithm search in conformational space[J]. J Comput Chem, 2001,22:1956-1970.
  • 9[9]Roe D C, Kuntz I D. BUILDER v.2: improving the chemistry of a de novo design strategy[ J]. J Comput Aided Mol Des,1995,9: 269-282.
  • 10[10]Pearlman D A, Murcko M A. CONCEPTS: new dynamic algorithm for de novo drug suggestion[ J]. J Comput Chem,1993,14:1184-1193.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部